|
|
|
| |
|
What is the Pipeline Project?
The Parkinson Pipeline Project
is a grassroots group of advocates whose goal is to provide
the patient perspective in the treatment development
process. Through education, consultation, and participation
with all stakeholders - including industry and the FDA - the
Parkinson Pipeline Project hopes to increase clinical trial
participation and accelerate approved treatment options.
New PD treatments are followed from pre-clinical development
to approval in the Pd Pipeline Database found on our
website.
More info...
"The missing ingredient in the development of new therapies is the voice of the patient."
Perry Cohen, Ph.D., Project Director
|
|
 |
"Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective"
W ritten
by Parkinson Pipeline Project members Published in
Neurotherapeutic, Vol. 4, No. 3, 2007.
Read the article
|
 |
 |
|
|

To
access PD Pipeline database records related to
these news items - please click on
- Eisai terminates
all E2007 phase III clinical trials for
Parkinson's.
Read press release. (4/11/08)

- Neurologix
Receives FDA Clearance to Initiate Phase
II Gene Therapy Trial
in Parkinson's Disease Subjects. Read press release.
(3/27/08)
- Sponsor receives FDA Not
Approvable Letter for Istradefylline
(KW-6002).
Read press release (3/9/08)

- "Common High Blood Pressure
Treatment Seems to Reduce Risk of
Parkinson’s Disease: What Does It Mean for
PD Patients? " Read an Interview of Dr.
James Surmeier by the Michael J Fox
Foundation.
Read press release
(2/29/08)
- FDA grants Solvay Fast
Track designation for its development
program for Duodopa (levodopa/carbidopa
intestinal gel) for treatment of motor
fluctuations associated with advanced
Parkinson's disease
Read press release
(2/18/08)
-
FDA
delays final approval of once-a-day Requip
XL (Jan 17, 2008)
Read the full article

- Phytopharm (UK) was awarded a grant from
the The Michael J. Fox Foundation to
support the development of Cogane. Taken
orally, it is believed Cogane crosses the
blood-brain barrier and stimulates the
release of GDNF in the brain. (1/22/08) Read
the press release

-
FDA
Signals High Bar for Stem Cell Treatments.
Read full article and comments in Wall
Street Journal Health Blog.
-
UCB advises US-physicians to
down-titrate patients on Neupro(R) in
view of out-of-stock situation in the US.
UCB initiates recall of Neupro(R) batches,
which will lead to an out-of-stock situation in
the United States in late April. Patients
in the US are advised to contact their
healthcare provide)
r. Neupro(R) supply is
sufficient in other regions.
Read press
release (3/20/08)
Update on Neupro Recall (4/21/08) -
Supreme Court Declines to Hear Case on Access
to Experimental Medications for Terminally ill
Patients Read the full article (Jan
17, 2008)

|
|
 |
|
|
|
Your access to
and use of the information contained in this web site is subject to this Terms
and Conditions of Use Agreement. By accessing and using this web site, you
accept this Terms and Conditions of Use Agreement.
The contents of this website and
all communications with Parkinson Pipeline Project (PPP) are solely for
information purposes and are not intended as medical advice. While we make
every effort to assure that the information is accurate and up to date, an error
may >occasionally occur. All information and materials are provided AS IS
without any warranty of any kind. In no event will the PPP be held liable
for any damages arising out of information contained in our website.
If any
provision of this Terms and Conditions of Use Agreement is held to be unlawful,
void, or unenforceable, then such provision shall be deemed severed without
affecting the enforceability of all remaining provisions.
|
|
|
Copyright © 2004-2007 Parkinson Pipeline
Project.
All rights reserved. Revised:
05/01/08
|
|